Search Results
Dec 01, 2025, 09:00 ET 100,000 Participants and Counting: Massive Global Genetic Dataset Powers Discoveries in Parkinson's Disease
2025 /PRNewswire/ -- Researchers have reached a major milestone in the effort to understand and treat Parkinson's disease: more than 100,000 DNA samples from study participants around the world have now been genotyped and sequenced through the Global Parkinson's Genetics Program (GP2), a resource
More news about: Aligning Science Across Parkinson's
Dec 01, 2025, 09:00 ET Biocodex To Present New Data at the American Epilepsy Society (AES) 2025 Annual Meeting
chain.The Biocodex global organization comprises 1,700 employees who share common values, embodied in their daily missions and rooted in the company's DNA.To learn more about Biocodex visit:
More news about: Biocodex, Inc.
Dec 01, 2025, 08:45 ET Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
patients have at least one PSMA-negative tumor lesion. Ac-225 delivers high-linear-energy-transfer alpha particles that induce irreparable double-strand DNA breaks, offering superior potency over beta emitters like Lutetium-177 (177Lu), and has a shorter tissue path length that may reduce off-target toxicity.
More news about: Actinium Pharmaceuticals, Inc.
Dec 01, 2025, 08:00 ET Consumer Edge Releases 2026 Restaurant Outlook: Value Dining Outperforms Hype as Chili's, Texas Roadhouse and Raising Cane's Show Momentum
consumers have adapted to years of inflationary pressures, and the brands seeing real momentum in this industry are those that treat value as part of their DNA, rather than a short-term promotion."Consumer Edge tracks more than 600 restaurant brands across all major categories, including casual dining,
More news about: Consumer Edge
Dec 01, 2025, 06:00 ET IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
payload provides a strong mechanistic rationale for combining IDE034 with IDEAYA's PARG inhibitor, IDE161. TOP1 inhibition induces replication stress and DNA damage, which can increase reliance on the PARG pathway; therefore, a IDE034 and IDE161 combination approach may enhance anti-tumor activity in patients
More news about: IDEAYA Biosciences, Inc.
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 27, 2025, 17:31 ET Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight
in recurrent pediatric cancers at the AACR 2024 conference.ONIVYDE is a cancer therapy that inhibits the TOP1 enzyme, which is essential for DNA replication and cell division. By blocking this enzyme, the drug prevents cancer cell proliferation, leading to cell death. In ONIVYDE, irinotecan is
More news about: DelveInsight Business Research LLP
Nov 27, 2025, 10:30 ET Pet DNA Testing Market to Reach $960.7 Million, Globally, by 2034 at 9.3% CAGR: Allied Market Research
the Report on Global Pet DNA Testing Market 2034 - https://www.alliedmarketresearch.com/request-sample/A325828Market IntroductionThe pet DNA testing market encompasses
More news about: Allied Market Research
Nov 26, 2025, 09:35 ET Exposing the Deadly Guesswork in Cancer Care: JOTO PR Signs First Ascent Biomedical
First Ascent Biomedical is revolutionizing cancer treatment with its AI-driven drug prediction platform. By integrating functional drug validation, DNA/RNA sequencing, and AI, the company identifies personalized therapies for all solid and liquid tumors, delivering actionable treatment plans to physicians
More news about: JOTO PR
Nov 26, 2025, 08:32 ET Endora Launches Mission to Send Human Memories to the Moon
videos to written reflections — in space. Endora has partnered with LifeShip, a space time capsule company that sends symbolic human artifacts such as DNA, seeds, and art into space for preservation and future discovery. The memories collected through Endora's Kickstarter will join a LifeShip payload bound
More news about: Endora Technologies
Nov 26, 2025, 06:43 ET Noah Reports Q3 2025 Earnings: Solid Overseas AUA/AUM Growth, Global Booking Center Network Completed, and Full AI Integration Powering New Momentum
innovation, and capitalize on evolving client demand.Leverage AI as a strategic growth driver and fully embed it into the Company's organizational DNA, as the wealth management industry shifts from a human-driven model to an operations-driven one over the next 3–5 years.Activate its four global
More news about: Noah Holdings Limited
Nov 25, 2025, 17:31 ET Mitochondrial Myopathies Market to Register Stunning Growth at a CAGR of 26.5% During the Forecast Period (2025-2034) Driven by Recent Approvals and Pipeline Advancements and Rising Awareness | DelveInsight
muscles due to their high energy requirements. Mitochondria possess their own genetic material, known as mitochondrial DNA (mtDNA). However, their function is also regulated by nuclear DNA (nDNA), which oversees mtDNA maintenance, mitochondrial protein synthesis, and the formation and activity of respiratory
More news about: DelveInsight Business Research, LLP
Nov 25, 2025, 12:16 ET How AI-Powered Content Automation Generated $3.5M: Black Lotus Ventures Unveils the AI Strategy Behind Viral Product
Senegalese entrepreneur. They ordered the device. And within minutes, they knew they had something. "The product worked, but more importantly, it had the DNA of virality," Hadji observed.Their research revealed that the product belonged to a creator with a substantial following and strong content, but
More news about: Black Lotus Ventures
Nov 25, 2025, 11:30 ET Ollin inaugura sistema pioneiro de testes genéticos
operacional do novo equipamento é mais baixo, o que, aliado à maior velocidade de processamento, de comparação e análise dos milhões de fragmentos de DNA, contribui para democratizar o acesso da população brasileira a esse tipo de teste.68 genomas em 24 horasO
More news about: Ollin
Nov 25, 2025, 09:19 ET G-SHOCK Shrinks Its Most Iconic Watch to Ring Size with the New DWN5600
miniature module and battery. Despite its size, the battery remains replaceable, ensuring long-lasting performance.Staying true to G-SHOCK's DNA, the small but fully functional digital display shows time down to the second, along with calendar, dual time, and stopwatch capabilities. The three
More news about: Casio America, Inc.
Nov 25, 2025, 09:00 ET Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911
CDH17 monoclonal antibody capable of efficient internalization into tumor cells, a novel cleavable linker with high plasma stability, and a proprietary DNA topoisomerase I inhibitor payload, MF-6, specifically designed to overcome the multidrug resistance.Preclinical studies demonstrated that 7MW4911
More news about: Mabwell
Nov 25, 2025, 08:45 ET VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
soon."1. Grolleau E, et al. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules. 2023;13(8):1255. https://doi.org/10.3390/biom130812552.
More news about: VolitionRx Limited
Nov 25, 2025, 08:45 ET VolitionRx Limited annonce le premier contrat de vente des tests Nu.Q® Cancer pour la validation clinique en vue d'une utilisation pratique de soins courants
»1. Grolleau E, et al. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules. 2023;13(8):1255. https://doi.org/10.3390/biom130812552.
More news about: VolitionRx Limited
Nov 24, 2025, 16:30 ET Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
time to chemotherapy (TTC). In addition, a poster presentation will provide results of an exploratory analysis of early changes in circulating tumor DNA (ctDNA) and correlation to clinical outcomes.Verzenio (abemaciclib; CDK4/6 inhibitor)In a poster presentation, Lilly will
More news about: Eli Lilly and Company
Nov 24, 2025, 13:01 ET Stagwell Partners with Harvard's OpenDP to Guarantee Customer Privacy, Beginning with its Partnership with Palantir for the Future of Marketing
and allows us to maintain trust with shareholders and employees alike," shared John Kahan, Chief AI Officer of Stagwell. "Data privacy is core to our DNA."The Palantir-Stagwell partnership is already seeing client adoption of its early MVP model in the United States.About Harvard University's
More news about: Stagwell Inc.
Nov 24, 2025, 11:58 ET Enquyst Technologies Demonstrates First-in-Class, Chromatography-free Downstream Processing of a Monoclonal Antibody (mAb) with its Patented Isoelectric Point Purification (IPP) Technology Platform and Announces Receipt of a National Institute for Innovation in Manufacturing Biopharmaceutical (NIIMBL) Led Gates Grand Challenge Program Award
able to demonstrate that its IPP technology platform was able to meet or exceed results in the removal of Host Cell Protein (HCP) and Host Cell DNA (HC DNA) impurities, while increasing product yield. With further optimization of its IPP technology platform, Enquyst believes it can surpass these already
More news about: Enquyst Technologies
Nov 24, 2025, 10:38 ET Nokona Celebrates 100th Anniversary with Yearlong Centennial Experiences for Baseball Fans Everywhere
Our commitment to homegrown craftsmanship is a hallmark of Nokona. It is what my great-grandfather, grandfather, and dad instilled in the company's DNA; that won't change ever."There's no doubt that the Nokona Centennial "line-up" has something for everyone. Fast approaching is a never-before-seen
More news about: Nokona
Nov 24, 2025, 10:31 ET Biochips Market worth $21.36 billion by 2030 with 8.8% CAGR | MarketsandMarkets™
maintenance, and customization services supports faster, more efficient research and diagnostics.By type, the market is segmented into DNA Chips, Lab-on-a-Chip, Protein Chips, Tissue Arrays and Cell Arrays. The Lab-on-a-Chip segment is projected to grow at the highest rate during the forecast
More news about: MarketsandMarkets
Nov 24, 2025, 09:00 ET ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed "DNA surgery") with high safety profile, unmatched precision, and affordable access for genetic diseases with unmet needs. The Company's core areas of focus
More news about: ToolGen
Nov 24, 2025, 07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers -- Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 -
More news about: BioLineRx Ltd.